Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Moon Bo Kim"'
Autor:
Seok Jin Nam, Michael Bouvet, Chihiro Hozumi, Ji Sun Lee, Y U Sun, Quinhong Han, Moon Bo Kim, Hye In Lim, Norihiko Sugisawa, Hee Jun Choi, Shree Ram Singh, Hiroto Nishino, Robert M. Hoffman, Jun Yamamoto, Sachiko Inubushi, Yoshihiko Tashiro
Publikováno v:
Anticancer Research. 40:2481-2485
BACKGROUND/AIM In the present study, the breast cancer patient-derived orthotopic xenograft (PDOX) model was used to identify an effective drug for a highly aggressive triple negative breast cancer (TNBC). MATERIALS AND METHODS The TNBC tumor from a
Autor:
Ji Sun Lee, Song Cheol Kim, Jaewoo Kwon, Moon Bo Kim, Ki Byung Song, Dae Wook Hwang, Yejong Park, Woohyung Lee, Song Lee, Robert M. Hoffman, Eunsung Jun, Jae Hoon Lee
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific reports, vol 10, iss 1
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific reports, vol 10, iss 1
The prognosis for patients with pancreatic cancer is extremely poor, as they are resistant to first line chemotherapy. The long-term goal of this study was to identify effective combination chemotherapy for pancreatic cancer using pancreatic cancer s
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1760
The histoculture drug response assay (HDRA) has been correlated clinically to a number of cancer types (please see Chaps. 7 - 11 of the present volume). The present chapter reviews the clinical trials of the HDRA for ovarian cancer. A prospective cli
Publikováno v:
3D Sponge-Matrix Histoculture ISBN: 9781493977437
The histoculture drug response assay (HDRA) has been correlated clinically to a number of cancer types (please see Chaps. 7 - 11 of the present volume). The present chapter reviews the clinical trials of the HDRA for ovarian cancer. A prospective cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3407ee1b22ada420aae55ab495e4355c
https://doi.org/10.1007/978-1-4939-7745-1_8
https://doi.org/10.1007/978-1-4939-7745-1_8
Autor:
Robert M. Hoffman, Song Cheol Kim, Soyeon An, Hyun Ju Yoo, Ji Sun Won, In Kyong Shim, Seung-Mo Hong, Eunsung Jun, Moon-Bo Kim, Suhwan Chang
Publikováno v:
Oncotarget
Tumors from 25 patients with pancreatic cancer were used to establish two patient-derived xenograft (PDX) models: orthotopic PDX (PDOX) and heterotopic (subcutaneous) PDX (PDHX). We compared gene expression by immunohistochemistry, single-nucleotide
Autor:
Dong-Hyung Cho, Jin Cheon Kim, Tae Won Kim, Seon Ae Roh, Moon Bo Kim, Yong Sik Yoon, Chan Wook Kim
Publikováno v:
Anticancer research. 37(3)
AIM The present study investigated how well the results of integrative tumor-response assay (ITRA) compared to those of clinical response to chemotherapy in patients with metastatic colorectal cancer (CRC). PATIENTS AND METHODS A total of 129 patient
Autor:
Eunsung, Jun, Jaeyoon, Jung, Seong-Yun, Jeong, Eun Kyung, Choi, Moon Bo, Kim, Ji Sun, Lee, Seung-Mo, Hong, Hyang Sook, Seol, Changmo, Hwang, Robert M, Hoffman, In Kyong, Shim, Suhwan, Chang, Song Cheol, Kim
Publikováno v:
Anticancer research. 36(2)
To effectively use pancreatic cancer patient-derived xenograft (PDX) models in translational research, successful PDX engraftment of surgical specimens in immune-deficient mice is needed.A total of 102 patients underwent pancreatic cancer resection u
Publikováno v:
Cancer research and treatment. 33(5)
Purpose Cancers are highly individual in their response to chemotherapy, however attempts to predict tumor response to drugs using in vitro cell culture have largely failed. A new technology, the histoculture drug response assay (HDRA), appears to ha
Autor:
Yoo M. Lee, Jin C. Kim, Jung S. Lee, Dae D. Kim, Seon Y. Kim, Moon Bo Kim, Dong H. Cho, Seong G. Ro, Tae Won Kim, Yong S. Kim
Publikováno v:
International Journal of Colorectal Disease. 24:209-218
This study was to evaluate the efficacy of histone deacetylase (HDAC) inhibitors in colorectal cancer together with other established regimens. Chemosensitivities of 114 colorectal cancer patients to established regimens (fluorouracil (5-FU with leuc
Publikováno v:
Anticancer research. 34(12)
Breast cancer can be divided into four subtypes: luminal-A, luminal-B, HER-2 enriched and triple negative breast cancer (TNBC) by the presence or absence of receptors. Each subtype has a typical clinical behavior and prognosis. Many chemotherapeutic